Abstract: Various compositions and methods are provided to alleviate one or more symptoms associated with hyposalivation and/or xerostomia. Preferred compositions and methods employ one or more plant pulp products and/or a proanthocyanidin at a concentration effective to reduce or eliminate the symptoms. Especially preferred product components are isolated from a fruit and/or seed (e.g., grape, cranberry, blue berry, black berry, etc.), and where a second component is is preferably a freeze-dried pulp from a citrus fruit (e.g., lemon, orange, lime, grapefruit, tangerine, mandarin orange, ugli fruit, etc.) not containing peel or juice therein.
Abstract: A method of treating scar tissue by applying a composite sheet for delivering therapeutic agents to the skin is disclosed. The composite sheet comprises a flexible porous polymer for holding and releasing the therapeutic agent in a polymer enrobing material. Microchannels pass through the polymer enrobing material and flexible porous polymer to promote the release of the therapeutic agent. The composite sheet is capable of releasing the therapeutic agent for periods of about 0 to about 30 days.
Abstract: Implant devices for intravesical administration and local drug delivery. The device has a body which includes a hollow tube formed of a biocompatible material; at least one reservoir in the tube which contains a drug; and one or more apertures through which the drug can be released. The device is configured for minimally invasive insertion into a body cavity, such as the bladder. The hollow tube may be elastomeric to permit the device to be elastically deformed from its initial shape into an elongated shape for passage through a catheter, where following such passage the device can return to or toward its initial shape to facilitate retention of the device in the body cavity. The body may have a narrow, elongated shape effective to permit insertion of the drug delivery device through a catheter without necessarily deforming the body, yet include flexible projections which effect retention within the body cavity.
Type:
Grant
Filed:
August 8, 2014
Date of Patent:
February 7, 2017
Assignees:
Massachusetts Institute of Technology, Children's Medical Center Corporation
Inventors:
Heejin Lee, Karen Daniel, Hong Linh Ho Duc, Michael J. Cima, Mario Castillo, Steven Froelich, Jordan Dimitrakov, Grace Y. Kim
Abstract: The invention concerns a transdermal delivery system for controlled dispensing of an active substance to and through a porous surface. A certain amount of fluid comprising at least one active substance and at least one solvent is dispensed into an administration reservoir. In the administration reservoir the at least one solvent is separated from the administration reservoir by a solvent recovery means such that the active substance achieves a certain level on an interface device which is permeable for the one active substance. Thereby the active substance is absorbable via diffusion from the interface device by a porous surface to be treated.
Type:
Grant
Filed:
June 22, 2015
Date of Patent:
January 31, 2017
Assignee:
CHRONO THERAPEUTICS INC.
Inventors:
Werner Zumbrunn, Georgios Imanidis, Guy Dipierro, Hans Werner Van De Venn
Abstract: Systems and methods for synchronizing the administration of compounds with the human body's natural circadian rhythms and addiction rhythms to counteract symptoms when they are likely to be at their worst by using an automated and pre programmable transdermal or other drug administration system.
Abstract: The present invention relates to a nail polish composition, comprising at least one high gloss film forming agent chosen from an esterified styrene maleic anhydride copolymer, a non-esterified styrene maleic anhydride copolymer and mixtures thereof, at least one co-film forming agent chosen from an epoxy resin, optionally, at least one plasticizer, at least one solvent, and optionally, at least one colorant, wherein the composition does not require use of nitrocellulose and can be used to makeup or protect nails. Such compositions impart high gloss, good adhesion and long wear properties.
Type:
Grant
Filed:
April 30, 2010
Date of Patent:
December 13, 2016
Assignee:
L'OREAL
Inventors:
Luis Ortega, Hy Si Bui, Ram Hariharan, Mohamed Kanji
Abstract: Nutritional fat or oil-based compositions for increasing HDL cholesterol, decreasing total cholesterol (TC), LDL cholesterol and decreasing the LDL/HDL cholesterol ratio in human plasma are described. The compositions can advantageously include at least 10% of myristic acid and/or lauric acid in which at least 3% of said fatty acid composition is myristic acid and at least 3% is lauric acid; in some cases at least 1% by weight myristic acid and/or lauric acid is esterified at the sn-2 position in triglyceride molecules. The compositions also include between 5% and 40% by weight linoleic acid, and typically further include at least 10% by weight monounsaturated fatty acids and between 15% and 55% by weight total saturated fatty acids. The sum of weight percentages for saturated, monounsaturated and polyunsaturated fatty acids equals 100%. In desirable cases, the composition is substantially cholesterol-free.
Abstract: A method for reducing human or animal weight from body fat, comprising providing a caloric source having a mild flavor or less flavor, other than sweetness or saltiness, at a time different from meal time and in an amount sufficient to provide a significant fraction of total daily caloric consumption, while eating normal food at meal times.
Abstract: Devices for administration of one or more active agents to the skin or mucosa of a host are formed in the nature of a double-disk patch. One outer layer functions as the primary adhesive layer for adhering the patch to the host. The other inner layer contains at least one active agent to be administered to the host. The inner layer is bonded to the outer layer through an opening provided in an interposed active agent impermeable release layer. The release layer separates a circumferential portion of the active agent containing inner layer from the outer adhesive layer to inhibit migration of the active agent therebetween.
Abstract: The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and is characterized by a considerably increased utilization of the active substance.
Type:
Grant
Filed:
November 7, 2007
Date of Patent:
April 12, 2016
Assignee:
PURDUE PHARMA L.P.
Inventors:
Thomas Hille, Michael Horstmann, Walter Mueller
Abstract: The present invention provides a composition for an oily foamable aerosol, characterized in that the composition comprises a fat or oil, and a polyglycerol fatty acid ester and/or an organic and fatty acid esters of glycerol; and an aerosol comprising the composition as defined in above and a propellant.
Abstract: A tansdermal delivery device for effectively treating seasonal allergic rhinitis and chronic idiopathic urticariain in humans is disclosed and methods thereof.
Abstract: Hydrogel compositions are provided (a) that have a continuous hydrophobic phase and a discontinuous hydrophilic phase, (b) that have a discontinuous hydrophilic phase and a continuous hydrophilic phase, or (c) that are entirely composed of a continuous hydrophilic phase. The hydrophobic phase, if present, is composed of a hydrophobic polymer, particularly a hydrophobic pressure-sensitive adhesive (PSA), a plasticizing elastomer, a tackifying resin, and an optional antioxidant. The discontinuous hydrophilic phase, if present, is composed of a crosslinked hydrophilic polymer, particularly a crosslinked cellulosic polymer such as crosslinked sodium carboxymethylcellulose. For those hydrogel compositions containing a continuous hydrophilic phase, the components of the phase include a cellulose ester composition or an acrylate polymer or copolymer, and a blend of a hydrophilic polymer and a complementary oligomer capable of hydrogen bonding thereto.
Type:
Grant
Filed:
May 10, 2013
Date of Patent:
February 16, 2016
Assignees:
A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences, Corium International, Inc.
Inventors:
Gary W. Cleary, Shoreh Parandoosh, Mikhail M. Feldstein, Anatoly E. Chalykh, Nicolai A. Platè, Valery G. Kulichikhin
Abstract: Dosage forms having a core having a surface having means for controlling release(s) on an active agent(s); methods of manufacturing, tools used in manufacturing; and uses of the dosage forms are described.
Abstract: Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval.
Type:
Grant
Filed:
March 25, 2010
Date of Patent:
December 1, 2015
Assignee:
Agile Therapeutics, Inc.
Inventors:
Thomas M. Rossi, Marie Foegh, Agis Kydonieus
Abstract: Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval.
Type:
Grant
Filed:
October 7, 2009
Date of Patent:
December 1, 2015
Assignee:
Agile Therapeutics, Inc.
Inventors:
Thomas M. Rossi, Marie Foegh, Agis Kydonieus
Abstract: Dosing regimen for transdermal delivery of hormones comprising a monthly treatment cycle with a fixed treatment interval and a variable rest interval.
Type:
Grant
Filed:
October 7, 2009
Date of Patent:
November 24, 2015
Assignee:
Agile Therapeutics, Inc.
Inventors:
Thomas M. Rossi, Marie Foegh, Agis Kydonieus
Abstract: A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.
Type:
Grant
Filed:
July 30, 2013
Date of Patent:
November 24, 2015
Assignee:
ManKind Corporation
Inventors:
Chad C. Smutney, P. Spencer Kinsey, Carl R. Sahi, Benoit Adamo, John M. Polidoro, Scott McLean, Dennis Overfield, Kelly S. Kraft, Karla Somerville